Genexine Inc
KOSDAQ:095700
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
M
|
Mideast Portfolio Management Ltd
BSE:526251
|
IN |
|
G
|
Guangdong Shirongzhaoye Co Ltd
SZSE:002016
|
CN |
|
SK Hynix Inc
F:HY9H
|
KR |
Genexine Inc
Other
Genexine Inc
Other Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
G
|
Genexine Inc
KOSDAQ:095700
|
Other
₩823.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Celltrion Inc
KRX:068270
|
Other
₩1.5T
|
CAGR 3-Years
163%
|
CAGR 5-Years
41%
|
CAGR 10-Years
28%
|
|
|
O
|
OliX Pharmaceuticals Inc
KOSDAQ:226950
|
Other
-₩539.2m
|
CAGR 3-Years
-48%
|
CAGR 5-Years
-58%
|
CAGR 10-Years
N/A
|
|
|
V
|
Voronoi Inc
KOSDAQ:310210
|
Other
-₩23m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Other
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
A
|
ABL Bio Inc
KOSDAQ:298380
|
Other
-₩50.5m
|
CAGR 3-Years
-63%
|
CAGR 5-Years
-32%
|
CAGR 10-Years
N/A
|
|
Genexine Inc
Glance View
Genexine, Inc. engages in research and development of therapeutic vaccines hybrid Fc fusion proteins (hyFc) and DNA (deoxyribonucleic acid) therapeutic vaccines. The company is headquartered in Seongnam, Gyeonggi-Do. The company went IPO on 2009-09-15. The firm operates its business through two segments. The New Drug Development segment engages in human growth hormone, neutropenia treatment, anemia treatment, anticancer immunotherapy, hyFc platform, and other technology transfers. In addition, this segment sells the technical property rights of follicle-stimulating hormone. The company also engages in cell line construction and sample production, project development, animal testing, human growth hormone development, and government agency research. The Medical Consumables segment produces and sells medical consumables such as medicine bags.
See Also
What is Genexine Inc's Other?
Other
823.7m
KRW
Based on the financial report for Dec 31, 2025, Genexine Inc's Other amounts to 823.7m KRW.
